Steven Hughes Biography and Net Worth

Insider of Avidity Biosciences

Dr. Steve Hughes, Chief Medical Officer, joined Avidity Biosciences in February 2022. Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams. He has contributed to over 50 clinical trials for more than 25 drugs across all stages of drug development and in multiple therapeutic areas including cardiovascular, neurology and several rare diseases with successful license approvals for several rare disease drugs. Dr. Hughes’s previous positions include the Chief Medical Officer at Arcturus and Organovo, Chief Clinical Development Officer at Ionis Pharmaceuticals and clinical leadership positions at Biogen, CSL Behring and Sanofi. Dr. Hughes is board certified in pharmaceutical medicine and received his medical degree from Imperial College, London. He also has an MBA from Imperial College Business School.

What is Steven George Hughes' net worth?: The estimated net worth of Steven George Hughes is at least $2.35 million as of March 20th, 2025. Dr. Hughes owns 72,850 shares of Avidity Biosciences stock worth more than $2,348,684 as of March 26th. This net worth evaluation does not reflect any other assets that Dr. Hughes may own. Learn More about Steven George Hughes' net worth.
How do I contact Steven George Hughes?: The corporate mailing address for Dr. Hughes and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at amy@juniper-point.com. Learn More on Steven George Hughes' contact information.
Has Steven George Hughes been buying or selling shares of Avidity Biosciences?: During the last quarter, Steven George Hughes has sold $297,492.68 in shares of Avidity Biosciences stock. Most recently, Steven George Hughes sold 9,578 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $31.06, for a transaction totalling $297,492.68. Following the completion of the sale, the insider now directly owns 72,850 shares of the company's stock, valued at $2,262,721. Learn More on Steven George Hughes' trading history.
Who are Avidity Biosciences' active insiders?: Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Kathleen Gallagher (Insider), Steven Hughes (Insider), Arthur Levin (Insider), Michael MacLean (Chief Financial and Chief Business Officer), Teresa Mccarthy (Insider), and Tamar Thompson (Director). Learn More on Avidity Biosciences' active insiders.
Are insiders buying or selling shares of Avidity Biosciences?: During the last year, insiders at the biotechnology company sold shares 36 times. They sold a total of 869,535 shares worth more than $31,566,515.23. The most recent insider tranaction occured on March, 20th when insider Steven George Hughes sold 9,578 shares worth more than $297,492.68. Insiders at Avidity Biosciences own 3.7% of the company. Learn More about insider trades at Avidity Biosciences.
Information on this page was last updated on 3/20/2025.

Steven George Hughes Insider Trading History at Avidity Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/20/2025	Sell	9,578	$31.06	$297,492.68	72,850

Steven George Hughes Buying and Selling Activity at Avidity Biosciences

Avidity Biosciences Company Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $32.05

$31.73

$32.75

50 Day Range

MA: $31.31

$27.87

$35.11

2 Week Range

Now: $32.05

$21.56

$56.00

Volume

1,576,969 shs

Average Volume

1,354,912 shs

Market Capitalization

$3.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02